eagle-i University of Hawaii at ManoaUniversity of Hawaii at Manoa
See it in Search
This page is a preview of the following resource. Continue onto eagle-i search using the button on the right to see the full record.

Randomized phase III double blind trial evaluating selective COX-2 inhibition in COX-2 expressing advanced non-small cell lung cancer

eagle-i ID


Resource Type

  1. Clinical trial


  1. ClinicalTrials.gov url
  2. Intervention
  3. Intervention
  4. Intervention
    Gemcitabine hydrochloride
  5. Intervention
    Pemetrexed disodium
  6. Additional Topic(s)
    Antineoplastic combined chemotherapy protocols
  7. Resource Description
    RATIONALE: Pemetrexed disodium and celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving gemcitabine hydrochloride or pemetrexed disodium together with carboplatin is more effective with or without celecoxib in treating non-small cell lung cancer. PURPOSE: This randomized phase III trial is studying gemcitabine hydrochloride, pemetrexed disodium, and carboplatin to compare how well they work when given together with celecoxib or a placebo in treating patients with advanced non-small cell lung cancer.
  8. Contact
    Berenberg, Jeffrey
  9. PI
    Berenberg, Jeffrey
  10. Topic
    lung cancer
  11. Study Population
    Males and females aged 18 and older with histologically or cytologically confirmed non-small cell carcinoma of the lung, including the following cell types: adenocarcinoma, large cell carcinoma, squamous cell carcinoma, or a mixture of these types.
  12. Website(s)
  13. Funded by
    Cancer Trials Support Unit
  14. Phase
    Phase 3 clinical trial
  15. Performed by
    Clinical Protocol & Data Management Shared Resource
Provenance Metadata About This Resource Record
Copyright © 2016 by the President and Fellows of Harvard College
The eagle-i Consortium is supported by NIH Grant #5U24RR029825-02 / Copyright 2016